Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.


HARMONY BIOSCIENCES HOLDINGS

Nasdaq / Health Care / Pharmaceuticals

Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to HRMY. HRMY was compared to 198 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. HRMY has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make HRMY suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

HRMY had positive earnings in the past year.
In the past year HRMY had a positive cash flow from operations.
Of the past 5 years HRMY 4 years were profitable.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

With an excellent Return On Assets value of 14.56%, HRMY belongs to the best of the industry, outperforming 95.96% of the companies in the same industry.
With an excellent Return On Equity value of 22.07%, HRMY belongs to the best of the industry, outperforming 92.93% of the companies in the same industry.
The Return On Invested Capital of HRMY (18.94%) is better than 93.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HRMY is significantly below the industry average of 41.61%.
The last Return On Invested Capital (18.94%) for HRMY is above the 3 year average (18.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.56%
ROE 22.07%
ROIC 18.94%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

HRMY's Profit Margin of 20.36% is amongst the best of the industry. HRMY outperforms 92.42% of its industry peers.
HRMY's Profit Margin has improved in the last couple of years.
HRMY's Operating Margin of 29.09% is amongst the best of the industry. HRMY outperforms 93.43% of its industry peers.
In the last couple of years the Operating Margin of HRMY has declined.
HRMY has a better Gross Margin (78.06%) than 84.34% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.09%
PM (TTM) 20.36%
GM 78.06%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

8

2. Health

2.1 Basic Checks

HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HRMY has more shares outstanding
HRMY has less shares outstanding than it did 5 years ago.
HRMY has a better debt/assets ratio than last year.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 5.14 indicates that HRMY is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.14, HRMY belongs to the best of the industry, outperforming 82.32% of the companies in the same industry.
HRMY has a debt to FCF ratio of 0.82. This is a very positive value and a sign of high solvency as it would only need 0.82 years to pay back of all of its debts.
HRMY has a Debt to FCF ratio of 0.82. This is amongst the best in the industry. HRMY outperforms 94.95% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that HRMY is not too dependend on debt financing.
The Debt to Equity ratio of HRMY (0.25) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.82
Altman-Z 5.14
ROIC/WACC1.93
WACC9.84%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

HRMY has a Current Ratio of 3.31. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HRMY (3.31) is comparable to the rest of the industry.
HRMY has a Quick Ratio of 3.27. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a better Quick ratio (3.27) than 60.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.31
Quick Ratio 3.27
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

9

3. Growth

3.1 Past

HRMY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.82%.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.80%.
The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)22.8%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%

3.2 Future

HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.90% yearly.
Based on estimates for the next years, HRMY will show a very strong growth in Revenue. The Revenue will grow by 21.10% on average per year.
EPS Next Y25.16%
EPS Next 2Y30.64%
EPS Next 3Y31.63%
EPS Next 5Y36.9%
Revenue Next Year17.81%
Revenue Next 2Y18.1%
Revenue Next 3Y18.92%
Revenue Next 5Y21.1%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.76 indicates a correct valuation of HRMY.
Compared to the rest of the industry, the Price/Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 87.88% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of HRMY to the average of the S&P500 Index (23.99), we can say HRMY is valued slightly cheaper.
A Price/Forward Earnings ratio of 7.81 indicates a rather cheap valuation of HRMY.
92.42% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (20.35), we can say HRMY is valued rather cheaply.
Industry RankSector Rank
PE 12.76
Fwd PE 7.81
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 90.40% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 91.92% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.78
EV/EBITDA 6.63
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 31.63% in the coming years.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y30.64%
EPS Next 3Y31.63%

0

5. Dividend

5.1 Amount

No dividends for HRMY!.
Industry RankSector Rank
Dividend Yield N/A